Cite
Lawal B, Lee CY, Mokgautsi N, et al. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications. Front Oncol. 2021;11:656738doi: 10.3389/fonc.2021.656738.
Lawal, B., Lee, C. Y., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. S. (2021). mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications. Frontiers in oncology, 11656738. https://doi.org/10.3389/fonc.2021.656738
Lawal, Bashir, et al. "mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications." Frontiers in oncology vol. 11 (2021): 656738. doi: https://doi.org/10.3389/fonc.2021.656738
Lawal B, Lee CY, Mokgautsi N, Sumitra MR, Khedkar H, Wu ATH, Huang HS. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications. Front Oncol. 2021 Mar 26;11:656738. doi: 10.3389/fonc.2021.656738. eCollection 2021. PMID: 33842373; PMCID: PMC8034425.
Copy
Download .nbib